

Rheumatoid Arthritis

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

Trial Status
Completed

Trial Runs In
6 Countries

Trial Identifier
NCT02573012 2014-004673-16
MA29585

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IIIb/IV, two-arm, randomized, double-blind, placebo-controlled, parallel-group, international, multicenter trial compares the change in disease activity (as assessed by Disease Activity Score in 28 joints [DAS28] erythrocyte sedimentation rate [ESR]) from randomization to Week 24 post-randomization, in participants with stable low disease activity [LDA] (DAS28 ESR score less than or equal to [\leq] 3.2) who receive tocilizumab, and have been randomized to either continue or taper prednisone in a double-blinded fashion.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT02573012 2014-004673-16 MA29585
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
 \geq 18 Years

Healthy Volunteers
No